Our Story

Pioneering Innovation Since Our Inception.

Founded by a team of experts in pharmaceutical research, technology, and business, 3C Pharma was built on the belief that innovation and technology can drive significant improvements in the way drugs are developed, tested, and brought to market. From our early days as a niche consulting firm, we have grown into a leading provider of AI-powered solutions for the pharmaceutical and life sciences industries.

Our journey has been defined by a passion for solving the most complex problems facing the healthcare sector. Over the years, we have partnered with some of the world’s largest pharmaceutical organizations, helping them achieve success through digital transformation and advanced technologies. Today, 3C Pharma continues to expand its portfolio of services and products, driving innovation across the entire drug development and post-marketing lifecycle.

3C Pharma: A Timeline of Innovation and Excellence

1997 – 3C Pharma Founded

3C Pharma is founded, with Schering Plough as its first major client, marking the beginning of a journey in providing innovative technological solutions to the pharmaceutical industry.

1999 – Global Clinical Trial Management System (CTMS) Launched

3C Pharma designs and implements a proprietary Clinical Trial Management System (CTMS) with eight regional hubs, revolutionizing the way global clinical trials are managed.

2000 – PharmaPay Grants & Payments Launched in France

3C Pharma introduces PharmaPay in France, a groundbreaking platform to manage clinical trial payments, streamlining financial operations for the life sciences industry.

2002 – PharmaPay Goes Global

PharmaPay expands globally, now integrated with CTMS for patient treatment schedules and clinical trial forecasting, improving financial transparency and efficiency.

2005 – Digital Pen Technology for Agricultural Studies

3C Pharma pioneers the use of Digital Pen technology to collect trial data in agricultural studies, bringing innovation to the agricultural sector.

2007 – Digital Pen Applied to Patient Reported Outcomes (ePRO)

3C Pharma implements Digital Pen technology for Patient Reported Outcomes (ePRO), leading the way in digitizing patient data collection for clinical trials

2009 – myPROpad ePRO Launched

The myPROpad iPad solution is launched, allowing the collection of Patient Reported Outcomes (ePRO) in clinical trials for prestigious institutions such as Rutgers and Yale.

2011 – Custom Software for Novartis Ringfencing Strategy

3C Pharma develops custom software to implement KPMG’s Ringfencing strategy for Novartis, enhancing regulatory and financial compliance.

2013 – myPROpad Enhancements for Specialized Clinical Trials

myPROpad is enhanced for specialized octogenarian clinical trials, improving usability for elderly patients in complex studies.

2014 – myPROpad Replaces PHT in Complex Clinical Trials

myPROpad replaces PHT in a highly complex clinical trial, addressing patient objections and improving the overall trial experience.

2017 – myPROpad Selected for Merck Global Trials

myPROpad is chosen for multiple Merck global clinical trials, leveraging its multi-lingual capabilities to support diverse patient populations worldwide.

2020 – Rapid Implementation of Virtual Visits During COVID-19

3C Pharma is recognized by Merck for going “above and beyond” to quickly implement Virtual Visits in ongoing clinical trials during the COVID-19 pandemic, ensuring trial continuity.

2023 – First-of-Its-Kind Veeva Implementation

3C Pharma architects a groundbreaking Veeva implementation for Medical Affairs, integrating with four commercial systems globally—a first for Veeva—enhancing cross-functional operations for pharmaceutical companies..

Get in Touch

Ready to Transform Your Life Sciences Operations?

If you’re looking for innovative technology solutions to accelerate your pharmaceutical or life sciences business, we would love to hear from you. Contact us today to learn more about how 3C Pharma can help you achieve your goals and stay ahead in a fast-paced industry.